See the DrugPatentWatch profile for Follitropin
Will follitropin alfa lose patent protection in Europe, and when?
The available information here does not include any details on the specific patent(s) covering follitropin alfa in Europe or their expiry dates, so the timing of patent loss cannot be determined from the provided material.
Which European protections usually control generic or biosimilar entry?
In Europe, market entry timing for medicines like follitropin alfa is commonly affected by a mix of:
- Patent expiry for the original product (and any follow-on patents)
- Supplementary Protection Certificates (SPCs), which can extend exclusivity beyond the base patent term
- Regulatory and marketing exclusivity periods (depending on the product history and jurisdiction)
- Ongoing litigation that can delay entry even after a scheduled expiry
Without the underlying patent/SPC numbers for follitropin alfa in Europe, it’s not possible to map out the exact exclusivity timeline.
What matters for a “biosimilar” drug versus a “generic”?
Follitropin alfa is a biologic drug (recombinant follicle-stimulating hormone), so “generic” typically does not apply the same way as for small-molecule drugs. Entry is usually through biosimilar pathways, where patent/SPC status and any court rulings are major drivers of when competitors can sell.
To answer whether/when biosimilars can enter, you need the specific European patents/SPCs covering the relevant product and the specific member-state timing.
How to get the exact Europe patent-loss date (what to look up)
If you want the precise “patent loss in Europe” date, the key items to identify are:
- The European patent numbers covering follitropin alfa (including key claim scope)
- Whether any SPCs were granted (and their expiry)
- Whether there are any court proceedings related to those rights
- The specific trade name/product (because patents can attach to different formulations or manufacturing/indication claims)
If you share details, I can pinpoint the timeline
If you provide any of the following, I can help determine the expected Europe patent-loss (and likely biosimilar entry) timing more concretely:
- The brand name you mean (e.g., the specific follitropin alfa product)
- Country focus (EU-wide vs a specific country, such as UK, Germany, France, etc.)
- Patent/SPC numbers (or a link to the patent record)
Sources
No sources were provided in the prompt, so I cannot cite any.